文献速递类风湿关节炎

接受Janus激酶抑制剂治疗的类风湿关节炎患者在BNT162b2疫苗接种后显示体液免疫应答降低

Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本研究比较了12例接受Janus激酶抑制剂治疗并接种两剂BNT162b2疫苗的类风湿关节炎患者与26例接种相同疫苗的健康个体的体液免疫应答,发现患者组抗刺突IgG抗体水平和中和能力均降低,且B细胞对SARS-CoV-2刺突蛋白的应答性也降低。

要点

  • 接受JAK抑制剂治疗的RA患者接种BNT162b2后抗刺突IgG抗体水平和中和能力低于健康个体。
  • RA患者B细胞对SARS-CoV-2刺突蛋白的应答性降低。
  • JAK抑制剂治疗的RA患者接种BNT162b2后体液免疫应答受到抑制。

核心结论

  • 接受JAK抑制剂治疗的RA患者在BNT162b2疫苗接种后显示体液免疫应答受到抑制,表现为抗刺突抗体的数量和质量均降低。

研究设计与样本

  • 研究收集了12例接受Janus激酶抑制剂治疗并接种两剂BNT162b2疫苗的RA患者以及26例接种相同疫苗的健康个体的血浆样本。

主要发现

  • 与健康个体相比,接受JAK抑制剂治疗的RA患者抗刺突IgG抗体水平和中和能力降低。
  • RA患者B细胞对SARS-CoV-2刺突蛋白的应答性降低。

关键数值与推荐

  • 采用ELISA定量抗体滴度,血浆中和试验测定病毒中和能力,定量PCR分析B细胞活化及生发中心反应相关基因表达变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The mRNA-based COVID-19 vaccines are now employed globally and have shown high efficacy in preventing SARS-CoV-2 infection. However, less is known about the vaccine efficacy in immune-suppressed individuals. This study sought to explore whether humoral immunity to the COVID-19 vaccine BNT162b2 is altered in RA patients treated with Janus kinase inhibitors by analysing their antibodies titre, neutralization activity and B cell responses. METHODS: We collected plasma samples from 12 RA patients who were treated with Janus kinase inhibitors and received two doses of the BNT162b2 vaccine, as well as 26 healthy individuals who were vaccinated with the same vaccine. We analysed the quantity of the anti-spike IgG and IgA antibodies that were elicited following the BNT162b2 vaccination, the plasma neutralization capacity and the responsiveness of the B-lymphocytes. We used ELISA to quantify the antibody titres, and a plasma neutralization assay was used to determine the virus neutralization capacity. Alteration in expression of the genes that are associated with B cell activation and the germinal centre response were analysed by quantitative PCR. RESULTS: Reduced levels of anti-spike IgG antibodies and neutralization capacity were seen in the RA patients who were treated with JAK inhibitors in comparison with healthy individuals. Furthermore, B cell responsiveness to the SARS-CoV-2 spike protein was reduced in the RA patients. CONCLUSION: RA patients who are treated with JAK inhibitors show a suppressed humoral response following BNT162b2 vaccination, as revealed by the quantity and quality of the anti-spike antibodies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Iancovici L, Khateeb D, Harel O, et al. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination. Rheumatology (Oxford). 2022. PMID: 34849628. doi:10.1093/rheumatology/keab879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。